 | | Vol. 21.32 – 30 November, 2020 |
| |
|
|
| PAK4 knockout induced adhesion protein re-expression in endothelial cells, reduced vascular abnormalities, improved T cell infiltration and inhibits glioblastoma growth in mice.
[Nature Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers studied hundreds of hospitalized—and closely monitored—patients with cancer receiving hematopoietic cell transplantation as they recovered from chemotherapy and stem-cell engraftment.
[Nature] |
|
|
|
| Scientists established culture conditions that facilitate long-term expansion of human fetal hepatocytes as organoids, and they describe how to generate gene knockouts using CRISPR–Cas9 in both human fetal hepatocyte and adult liver ductal organoid systems.
[Nature Protocols] |
|
|
|
| When co-administered with transplanted human induced pluripotent stem cell-derived human neural stem cells in a mouse model of a prototypical neurodegenerative disease, the agonist enhanced migration, dissemination, and integration of donor-derived cells into the diseased cerebral cortex where their secreted cross-corrective enzyme mediated a therapeutic impact unachieved by cells alone.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers described transplant characteristics of pediatric patients who underwent hematopoietic stem cell transplantation in Switzerland and how these characteristics changed over time, compared self-reported pulmonary outcomes between transplanted and non-transplanted survivors, and investigated risk factors for the reported pulmonary outcomes.
[Bone Marrow Transplantation] |
|
|
|
| Thirteen B-cell acute lymphoblastic leukemia patients with relapsed after allo-hematopoietic stem cell transplantation and thus were treated with donor-derived anti-CD19 CAR T-cell.
[Bone Marrow Transplantation] |
|
|
|
| Scientists demonstrated that combination treatment of macitentan and ETBR gene therapy inhibited invasion, but not proliferation, in cell culture and in a mouse model of tongue cancer.
[Scientific Reports] |
|
|
|
| Researchers developed transplantable hyaline-like cartilage constructs by stimulating MSC chondrogenic differentiation as cell sheets.
[Scientific Reports] |
|
|
|
| Scientists describe a new human surfactant air-liquid interface culture model based on H441 cells which successfully recapitulates the key characteristics of human alveolar cells in primary culture as evidenced by RNA and protein expression of alveolar cell markers.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
|
| Innate and innate-like cells with unique immune properties, such as natural killer (NK) cells, NKT cells, γδ T cells, and macrophages, are promising alternatives to αβ CAR-T adoptive therapy. Scientists review the applicability of these cells in the context of CAR therapy, focusing on therapies under development, the advantages of these approaches relative to conventional CAR-T cells, and their potential in allogeneic therapies.
[Trends in Pharmacological Sciences] |
|
|
|
| The authors summarize current vaccine recommendations for patients with hematologic malignancies including patients who undergo hematopoietic cell transplant.
[Blood Reviews] |
|
|
|
| Scientists review the potential mechanism of stem cells as new therapeutic agents in the treatment of diabetic nephropathy (DN). They also review recent findings and updated information about not only the utilization of stem cells on DN in both preclinical and clinical trials but limitations and future expectations of stem cell-based therapy for DN.
[Cell Death & Disease] |
|
|
|
T | Scientists review strategies under investigation in the prophylactic and therapeutic settings to improve the safety of CAR T-cells for acute lymphoblastic leukemia.
[Bone Marrow Transplantation] |
|
|
|
|
| Genprex, Inc. announced it has commenced clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer. Acclaim-1 is an open-label, multi-center Phase I/II clinical trial that combines Genprex’s lead drug candidate, REQORSA™ immunogene therapy with AstraZeneca PLC’s Tagrisso.
[Genprex, Inc.] |
|
|
|
| Be The Match BioTherapies as a preferred partner to provide consistent access to high-quality, healthy donor tissue and cell and gene therapy supply chain support.
[Be The Match BioTherapies] |
|
|
|
| Caribou Biosciences, Inc. announced the execution of an exclusive license agreement with Memorial Sloan Kettering Cancer Center under which Caribou has rights to fully human anti-CD371 scFvs and intellectual property related thereto in the field of allogeneic CD371-targeted cell therapies including CAR-T, CAR-NK, or iPSC-derived cell products.
[Caribou Biosciences, Inc.] |
|
|
|
|
| April 20 – April 22, 2021
Shenzhen, China |
|
|
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| | Axovia Therapeutics – London, England, United Kingdom |
|
|
|
| | LMU University Hospital Munich – Munich, Germany |
|
|
|
| | EnaraBio – Oxford, England, United Kingdom |
|
|
|
| | GlaxoSmithKline – Stevenage, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
